EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DLK1: a novel therapeutic target in cancer

James Frederick Henry Pittaway iD

Endocrine-Related Cancer · 22.04.2026 · 33 (5)

DOI: 10.1530/erc-25-0513 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, erschienen am 22.04.2026. Verfasst von James Frederick Henry Pittaway. Hauptthemen laut MEDLINE: Calcium-Binding Proteins, Neoplasms, Membrane Proteins. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graphical Abstract Abstract Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable transmembrane protein with tightly regulated, developmentally restricted expression. It is highly expressed during embryogenesis, where it plays a key role in controlling cellular differentiation and proliferation, but is largely silenced in adult tissues, persisting mainly within stem and progenitor compartments of endocrine organs. Notably, DLK1 is consistently re-expressed across a broad range of malignancies, with the highest prevalence observed in endocrine and neuroendocrine tumours, including adrenocortical carcinoma, phaeochromocytoma/paraganglioma, medullary thyroid carcinoma, and neuroblastoma. DLK1 expression is associated with adverse clinical outcomes and is increasingly implicated in maintaining a de-differentiated, stem-like tumour phenotype that might contribute to tumour progression and therapeutic resistance. The restricted expression of DLK1 in normal adult tissues, combined with its cell-surface localisation and functional relevance in tumour biology, makes it an attractive therapeutic target, particularly in endocrine malignancies where targetable options remain limited. Multiple DLK1-directed strategies are now advancing through preclinical and early clinical development, including afucosylated monoclonal antibodies, antibody–drug conjugates, dendritic cell vaccines, chimeric antigen receptor T-cell therapies, and radioimmunotherapy. Early-phase studies demonstrate encouraging safety profiles and signals of efficacy, with emerging evidence suggesting that tumour-specific factors – such as steroidogenesis, immune microenvironment, and drug efflux mechanisms – may influence response in endocrine cancers. This review collates current evidence on DLK1 biology and therapeutic targeting, with a focus on endocrine and neuroendocrine malignancies. We highlight key novel mechanistic insights, translational challenges, and future opportunities to exploit DLK1 as a precision therapeutic target in these high-need cancer subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium-Binding ProteinsNeoplasmsMembrane ProteinsHumansAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

DLK1cancertargettherapytreatment

Substanzen

DLK1 protein, humanCalcium-Binding ProteinsMembrane Proteins

Autor:innen und Institutionen

ORCID-Profile: James Frederick Henry Pittaway

Zitieren

APA

Pittaway, J. F. H. (2026). DLK1: a novel therapeutic target in cancer. Endocrine-Related Cancer, 33(5). https://doi.org/10.1530/erc-25-0513

Vancouver

Pittaway JFH. DLK1: a novel therapeutic target in cancer. Endocrine-Related Cancer. 2026;33(5). doi:10.1530/erc-25-0513

BibTeX
@article{Pittaway2026,
  author = {Pittaway, James Frederick Henry},
  title = {DLK1: a novel therapeutic target in cancer},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {5},
  doi = {10.1530/erc-25-0513}
}
Kostenlos starten →